Leptin Receptor Inhibitors
1 drugsAbout Leptin Receptor
The Leptin Receptor (LEPR) is a transmembrane receptor that regulates energy balance by binding the hormone leptin. This interaction initiates intracellular signaling cascades influencing appetite, metabolism, and reproductive function.
LEPR's role in energy homeostasis makes it a therapeutic target for metabolic dysregulation. Currently, there is no genetic evidence data available linking LEPR to specific diseases.
LEPR is targeted by one FDA-approved biologic drug, MYALEPT, marketed by CHIESI FARMACEUTICI SPA. This drug has applications beyond common metabolic disorders, suggesting potential in rarer conditions involving leptin deficiency.
Top Leptin Receptor Drugs
CHIESI FARMACEUTICI SPA is the only company with an approved drug targeting LEPR.
The market is highly concentrated, presenting a barrier to entry for new competitors.
Leptin Receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Leptin Receptor, using biologic (other) modality.
The absence of small molecule or antibody drugs represents a whitespace opportunity.
Leptin Receptor Clinical Trials 15 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Leptin Receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 9 | 5 | 1 | 3 | 83% |
| Phase 3 | 4 | 0 | 1 | 3 | 0% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Leptin Receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Leptin Receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Leptin Receptor Drug Approval Timeline (2014 - 2014)
The first and only drug, MYALEPT, was approved in 2014.
The approval timeline suggests a saturated market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Leptin Receptor. A trial counts if an approved drug acting on Leptin Receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.